TDMS Study 05037-03 Pathology Tables
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
Facility: Southern Research Institute
Chemical CAS #: 1825-21-4
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include 001 VEHICLE CONTROL
Include 004 VEHICLE CONTROL
Include 007 40 MG/KG
Include 010 40 MG/KG
Include 013 20 MG/KG
Include 016 20 MG/KG
Include 019 10 MG/KG
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50
Early Deaths
Moribund Sacrifice 17 13 4
Natural Death 4 2 2
Survivors
Terminal Sacrifice 29 35 44
Animals Examined Microscopically 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (1) (50)
Inflammation, Chronic 1 (2%)
Parasite Metazoan 2 (4%)
Intestine Large, Colon (49) (1) (49)
Inflammation, Chronic 1 (2%)
Parasite Metazoan 2 (4%) 2 (4%)
Intestine Large, Rectum (50) (1) (49)
Edema 1 (2%)
Inflammation, Chronic 2 (4%)
Parasite Metazoan 7 (14%) 9 (18%)
Intestine Small, Ileum (50) (1) (50)
Inflammation, Chronic 1 (2%)
Intestine Small, Jejunum (50) (1) (50)
Inflammation, Chronic 1 (2%)
Necrosis 1 (2%)
Liver (50) (50) (50)
Angiectasis 4 (8%) 2 (4%)
Basophilic Focus 42 (84%) 44 (88%) 45 (90%)
Clear Cell Focus 5 (10%) 3 (6%) 2 (4%)
Developmental Malformation 1 (2%) 5 (10%)
Eosinophilic Focus 1 (2%) 2 (4%)
Granuloma 29 (58%) 19 (38%) 24 (48%)
Hematopoietic Cell Proliferation 2 (4%) 4 (8%) 3 (6%)
Hepatodiaphragmatic Nodule 3 (6%) 7 (14%) 5 (10%)
Hyperplasia, Focal 4 (8%) 6 (12%) 5 (10%)
Inflammation, Chronic 11 (22%) 10 (20%) 12 (24%)
Inflammation, Chronic Active 1 (2%)
Mixed Cell Focus 4 (8%) 4 (8%)
Bile Duct, Hyperplasia 31 (62%) 27 (54%) 17 (34%)
Centrilobular, Atrophy 1 (2%) 1 (2%)
Centrilobular, Necrosis 1 (2%) 1 (2%) 1 (2%)
Hepatocyte, Pigmentation 18 (36%) 24 (48%)
Hepatocyte, Vacuolization Cytoplasmic 4 (8%) 3 (6%) 1 (2%)
Kupffer Cell, Pigmentation 3 (6%) 2 (4%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Lobules, Necrosis 2 (4%) 3 (6%) 1 (2%)
Oval Cell, Hyperplasia 1 (2%) 1 (2%)
Portal, Necrosis 1 (2%)
Mesentery (13) (3) (7)
Cyst 1 (8%)
Necrosis 1 (14%)
Fat, Inflammation, Chronic Active 2 (15%)
Fat, Necrosis 10 (77%) 3 (100%) 6 (86%)
Pancreas (50) (50)
Atrophy 11 (22%) 10 (20%)
Cytoplasmic Alteration 2 (4%)
Hyperplasia, Focal 3 (6%)
Inflammation, Chronic 3 (6%)
Duct, Hyperplasia 1 (2%)
Salivary Glands (50) (50)
Atrophy 3 (6%)
Duct, Dilatation 1 (2%) 1 (2%)
Stomach, Forestomach (50) (1) (50)
Edema 3 (6%) 1 (2%)
Foreign Body 1 (100%)
Inflammation, Chronic Active 1 (2%) 1 (100%) 1 (2%)
Ulcer 2 (4%) 1 (2%)
Mucosa, Hyperplasia 3 (6%) 1 (100%) 3 (6%)
Stomach, Glandular (50) (1) (50)
Erosion 2 (4%)
Mineralization 3 (6%)
Mucosa, Hyperplasia 1 (2%)
Tooth (2) (1)
Developmental Malformation 1 (100%)
Inflammation, Suppurative 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50)
Cardiomyopathy 20 (40%) 31 (62%)
Myocardium, Inflammation, Chronic 4 (8%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (50) (50) (50)
Hypertrophy, Focal 1 (2%)
Adrenal Gland, Cortex (50) (50) (50)
Accessory Adrenal Cortical Nodule 9 (18%) 13 (26%) 13 (26%)
Angiectasis 24 (48%) 30 (60%) 27 (54%)
Clear Cell Focus 4 (8%) 4 (8%) 4 (8%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Cyst 1 (2%)
Degeneration, Fatty 1 (2%)
Hematopoietic Cell Proliferation 2 (4%)
Hyperplasia, Focal 12 (24%) 13 (26%) 12 (24%)
Hypertrophy, Focal 1 (2%) 3 (6%) 4 (8%)
Necrosis 1 (2%)
Vacuolization Cytoplasmic, Diffuse 1 (2%)
Adrenal Gland, Medulla (50) (50) (50)
Angiectasis 1 (2%) 1 (2%) 1 (2%)
Hyperplasia 10 (20%) 18 (36%) 25 (50%)
Islets, Pancreatic (50) (50)
Hyperplasia 2 (4%)
Pituitary Gland (49) (50) (50)
Pars Distalis, Angiectasis 4 (8%) 7 (14%) 8 (16%)
Pars Distalis, Cyst 20 (41%) 27 (54%) 20 (40%)
Pars Distalis, Hyperplasia 9 (18%) 8 (16%) 8 (16%)
Pars Distalis, Pigmentation 9 (18%) 10 (20%) 9 (18%)
Pars Intermedia, Angiectasis 1 (2%) 1 (2%)
Pars Intermedia, Cyst 1 (2%) 2 (4%) 1 (2%)
Pars Intermedia, Pigmentation 1 (2%)
Pars Nervosa, Cyst 1 (2%)
Thyroid Gland (50) (2) (50)
Ultimobranchial Cyst 3 (6%) 1 (2%)
C-Cell, Hyperplasia 5 (10%) 13 (26%)
Follicle, Cyst 1 (2%)
Follicular Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (8) (50)
Ectasia 4 (8%) 2 (25%) 2 (4%)
Hyperplasia 1 (2%)
Inflammation, Chronic 3 (6%) 1 (13%) 5 (10%)
Inflammation, Suppurative 3 (6%) 4 (8%)
Ovary (50) (5) (50)
Cyst 1 (2%) 1 (20%) 6 (12%)
Uterus (50) (50) (50)
Abscess 2 (4%) 1 (2%) 2 (4%)
Angiectasis 1 (2%)
Cyst 1 (2%) 2 (4%)
Hemorrhage 3 (6%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - CONT
Hydrometra 7 (14%) 2 (4%) 6 (12%)
Hyperplasia, Cystic 13 (26%) 13 (26%) 20 (40%)
Inflammation, Suppurative 2 (4%)
Necrosis 1 (2%)
Myometrium, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50)
Hypercellularity 1 (2%) 2 (4%)
Hyperplasia, Reticulum Cell 3 (6%) 3 (6%)
Lymph Node (50) (11) (50)
Bronchial, Hemorrhage 1 (2%)
Bronchial, Pigmentation 1 (2%)
Inguinal, Hyperplasia, Plasma Cell 1 (2%) 1 (9%)
Lumbar, Hyperplasia, Plasma Cell 1 (9%)
Lumbar, Lymphatic, Dilatation 1 (9%)
Mediastinal, Hemorrhage 7 (14%) 2 (4%)
Mediastinal, Hyperplasia, Lymphoid 1 (2%)
Mediastinal, Hyperplasia, Plasma Cell 1 (9%) 2 (4%)
Mediastinal, Pigmentation 10 (20%) 1 (9%) 7 (14%)
Pancreatic, Hemorrhage 1 (9%)
Pancreatic, Hyperplasia, Plasma Cell 1 (2%)
Pancreatic, Infiltration Cellular, Histiocyte 1 (2%)
Pancreatic, Lymphatic, Dilatation 1 (2%)
Renal, Hemorrhage 1 (2%)
Renal, Pigmentation 1 (9%) 1 (2%)
Lymph Node, Mandibular (50) (3) (50)
Hemorrhage 1 (33%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 1 (33%) 2 (4%)
Hyperplasia, Plasma Cell 14 (28%) 1 (33%) 20 (40%)
Infiltration Cellular, Mast Cell 1 (2%)
Pigmentation 1 (2%)
Lymphatic, Dilatation 1 (2%) 1 (33%) 5 (10%)
Lymph Node, Mesenteric (49) (3) (50)
Hemorrhage 2 (4%) 1 (33%) 1 (2%)
Hyperplasia, Lymphoid 3 (6%)
Lymphatic, Dilatation 1 (2%)
Spleen (50) (10) (50)
Congestion 2 (4%)
Developmental Malformation 1 (10%)
Fibrosis 1 (2%)
Hematopoietic Cell Proliferation 15 (30%) 4 (40%) 6 (12%)
Hyperplasia, Re Cell 1 (2%)
Necrosis 1 (2%) 1 (10%)
Pigmentation, Hemosiderin 5 (10%) 2 (20%) 7 (14%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Lymphoid Follicle, Hyperplasia 2 (4%)
Thymus (47) (48)
Cyst 3 (6%) 2 (4%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (48) (21) (50)
Hyperplasia, Cystic 38 (79%) 15 (71%) 33 (66%)
Hyperplasia, Lobular 4 (8%) 2 (10%) 2 (4%)
Skin (50) (3) (50)
Hemorrhage 1 (33%)
Inflammation, Chronic 1 (2%)
Inflammation, Granulomatous 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (6) (50)
Calvarium, Osteopetrosis 5 (10%) 6 (100%)
Femur, Osteopetrosis 6 (12%) 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (4) (50)
Compression 6 (12%) 3 (75%) 4 (8%)
Degeneration, Focal 1 (2%)
Hemorrhage 1 (2%) 1 (2%)
Hydrocephalus 4 (8%) 1 (25%) 4 (8%)
Necrosis 1 (2%)
Pigmentation 1 (2%)
Meninges, Fibrosis 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (7) (50)
Congestion 2 (4%) 1 (14%) 1 (2%)
Edema 2 (4%)
Hemorrhage 1 (2%)
Infiltration Cellular, Histiocyte 24 (48%) 4 (57%) 31 (62%)
Inflammation, Chronic 12 (24%) 1 (14%) 18 (36%)
Inflammation, Suppurative 1 (14%) 1 (2%)
Pigmentation, Cholesterol 1 (2%)
Thrombosis 1 (2%)
Alveolar Epithelium, Hyperplasia 3 (6%) 2 (29%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Smooth Muscle, Hyperplasia 1 (2%)
Nose (49) (50) (50)
Developmental Malformation 1 (2%)
Exudate 3 (6%) 8 (16%) 7 (14%)
Foreign Body 1 (2%) 3 (6%) 1 (2%)
Fungus 1 (2%) 5 (10%) 1 (2%)
Inflammation, Chronic 5 (10%) 13 (26%) 11 (22%)
Glands, Hyperplasia 1 (2%)
Glands, Necrosis 1 (2%)
Mucosa, Hyperplasia 5 (10%) 2 (4%)
Mucosa, Metaplasia, Squamous 4 (8%)
Olfactory Epithelium, Pigmentation 46 (92%) 50 (100%)
Trachea (50) (50)
Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (4) (8)
Cataract 1 (100%) 3 (75%) 8 (100%)
Phthisis Bulbi 1 (25%)
Cornea, Inflammation, Chronic Active 1 (13%)
Cornea, Mineralization 1 (13%)
Retina, Atrophy 1 (100%) 3 (75%) 8 (100%)
Sclera, Mineralization 2 (25%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50)
Cyst 1 (2%) 1 (2%) 1 (2%)
Hydronephrosis 1 (2%) 1 (2%)
Inflammation, Acute 1 (2%)
Inflammation, Chronic 7 (14%) 11 (22%) 10 (20%)
Inflammation, Suppurative 1 (2%) 1 (2%) 1 (2%)
Mineralization 21 (42%) 24 (48%) 15 (30%)
Nephropathy 41 (82%) 48 (96%) 42 (84%)
Renal Tubule, Atrophy 1 (2%)
Renal Tubule, Degeneration 1 (2%)
Renal Tubule, Dilatation 1 (2%) 1 (2%) 1 (2%)
Renal Tubule, Pigmentation 43 (86%) 45 (90%)
Transitional Epithelium, Hyperplasia 4 (8%) 2 (4%)
Urethra (1)
Inflammation, Chronic 1 (100%)
Necrosis 1 (100%)
Urinary Bladder (50) (1) (49)
Hemorrhage 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS FEMALE VEHICLE 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Inflammation, Chronic 1 (2%)
Inflammation, Subacute 2 (4%)
Mucosa, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 10 MG/KG 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Moribund Sacrifice 23 21 14 5
Natural Death 3 5 7 27
Dosing Accident 4 2
Accidently Killed 5 2
Survivors
Terminal Sacrifice 24 20 24 14
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (50) (50)
Ulcer 1 (2%)
Intestine Large, Cecum (50) (49) (48) (50)
Edema 1 (2%) 1 (2%) 1 (2%)
Parasite Metazoan 2 (4%) 3 (6%)
Ulcer 2 (4%) 1 (2%)
Intestine Large, Colon (50) (50) (49) (49)
Parasite Metazoan 5 (10%) 2 (4%) 5 (10%)
Intestine Large, Rectum (50) (50) (49) (47)
Edema 1 (2%)
Parasite Metazoan 5 (10%) 6 (12%) 3 (6%) 3 (6%)
Lymphatic, Dilatation 1 (2%)
Liver (50) (50) (50) (50)
Angiectasis 4 (8%) 1 (2%) 2 (4%)
Basophilic Focus 27 (54%) 27 (54%) 26 (52%) 8 (16%)
Clear Cell Focus 14 (28%) 7 (14%) 6 (12%) 4 (8%)
Congestion 2 (4%) 2 (4%) 13 (26%)
Degeneration, Cystic 2 (4%) 5 (10%) 9 (18%) 6 (12%)
Eosinophilic Focus 3 (6%) 9 (18%) 9 (18%) 1 (2%)
Granuloma 19 (38%) 10 (20%) 6 (12%) 8 (16%)
Hematopoietic Cell Proliferation 4 (8%) 2 (4%) 2 (4%)
Hepatodiaphragmatic Nodule 2 (4%) 2 (4%) 1 (2%)
Hyperplasia, Focal 7 (14%) 5 (10%) 2 (4%)
Inflammation, Chronic 6 (12%) 8 (16%) 9 (18%) 4 (8%)
Inflammation, Chronic Active 1 (2%)
Mixed Cell Focus 1 (2%) 3 (6%) 1 (2%)
Bile Duct, Hyperplasia 45 (90%) 45 (90%) 44 (88%) 26 (52%)
Centrilobular, Atrophy 2 (4%) 5 (10%)
Centrilobular, Necrosis 6 (12%) 6 (12%) 17 (34%)
Hepatocyte, Pigmentation 1 (2%) 4 (8%)
Hepatocyte, Vacuolization Cytoplasmic 8 (16%) 2 (4%) 1 (2%) 2 (4%)
Kupffer Cell, Hyperplasia 3 (6%) 1 (2%) 4 (8%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 10 MG/KG 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Kupffer Cell, Pigmentation 1 (2%)
Lobules, Necrosis 2 (4%) 4 (8%) 1 (2%) 1 (2%)
Periportal, Inflammation, Chronic Active 1 (2%)
Portal, Necrosis 1 (2%)
Mesentery (11) (11) (5) (9)
Accessory Spleen 1 (9%) 1 (9%)
Fat, Inflammation, Pyogranulomatous 1 (9%)
Fat, Necrosis 6 (55%) 5 (45%) 4 (80%) 3 (33%)
Pancreas (49) (49) (49) (50)
Atrophy 14 (29%) 17 (35%) 19 (39%) 9 (18%)
Cytoplasmic Alteration 3 (6%) 2 (4%) 1 (2%)
Edema 1 (2%)
Fibrosis 1 (2%)
Focal Cellular Change 1 (2%) 3 (6%)
Hyperplasia, Focal 19 (39%) 17 (35%) 8 (16%) 1 (2%)
Infiltration Cellular, Histiocyte 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Salivary Glands (50) (50) (48) (50)
Atrophy 1 (2%) 1 (2%)
Stomach, Forestomach (50) (50) (50) (50)
Dysplasia 1 (2%)
Edema 1 (2%) 2 (4%) 4 (8%)
Erosion 2 (4%) 2 (4%)
Inflammation, Chronic 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%)
Mineralization 1 (2%)
Ulcer 3 (6%) 4 (8%) 2 (4%)
Mucosa, Hyperplasia 6 (12%) 7 (14%) 5 (10%)
Stomach, Glandular (50) (50) (50) (50)
Edema 1 (2%) 1 (2%)
Erosion 3 (6%) 1 (2%) 2 (4%)
Hemorrhage 1 (2%)
Inflammation, Chronic Active 2 (4%)
Mineralization 4 (8%) 3 (6%) 1 (2%) 1 (2%)
Ulcer 3 (6%) 1 (2%) 1 (2%) 3 (6%)
Mucosa, Hyperplasia 1 (2%)
Tooth (2) (1)
Developmental Malformation 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (4) (4) (5) (5)
Polyarteritis 4 (100%) 4 (100%) 4 (80%) 5 (100%)
Heart (50) (50) (49) (50)
Angiectasis 1 (2%)
Cardiomyopathy 33 (66%) 37 (74%) 36 (73%) 21 (42%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 10 MG/KG 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM - CONT
Thrombosis 1 (2%) 1 (2%)
Epicardium, Inflammation, Chronic 1 (2%)
Myocardium, Inflammation, Chronic 2 (4%) 3 (6%) 3 (6%) 7 (14%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (50) (50) (50)
Accessory Adrenal Cortical Nodule 14 (29%) 11 (22%) 8 (16%) 6 (12%)
Angiectasis 4 (8%) 2 (4%) 2 (4%) 4 (8%)
Clear Cell Focus 4 (8%) 5 (10%) 5 (10%) 3 (6%)
Congestion 2 (4%) 2 (4%)
Cyst 1 (2%)
Hematopoietic Cell Proliferation 2 (4%) 2 (4%) 1 (2%)
Hemorrhage 5 (10%)
Hyperplasia, Diffuse 1 (2%)
Hyperplasia, Focal 7 (14%) 10 (20%) 7 (14%) 2 (4%)
Necrosis 2 (4%) 1 (2%)
Vacuolization Cytoplasmic, Diffuse 3 (6%) 2 (4%) 1 (2%) 2 (4%)
Adrenal Gland, Medulla (50) (50) (50) (48)
Angiectasis 1 (2%) 1 (2%)
Cyst 1 (2%)
Hyperplasia 23 (46%) 26 (52%) 16 (32%) 9 (19%)
Infiltration Cellular, Lymphocyte 1 (2%)
Islets, Pancreatic (49) (49) (49) (50)
Cyst 1 (2%) 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia 8 (16%) 7 (14%) 8 (16%) 3 (6%)
Pituitary Gland (49) (50) (48) (50)
Pars Distalis, Angiectasis 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Pars Distalis, Cyst 5 (10%) 2 (4%) 4 (8%) 2 (4%)
Pars Distalis, Hemorrhage 1 (2%)
Pars Distalis, Hyperplasia 9 (18%) 9 (18%) 5 (10%) 2 (4%)
Pars Distalis, Necrosis 1 (2%)
Pars Distalis, Pigmentation 2 (4%) 1 (2%)
Pars Intermedia, Angiectasis 1 (2%) 1 (2%) 1 (2%)
Pars Intermedia, Hyperplasia 2 (4%)
Pars Nervosa, Cyst 1 (2%)
Thyroid Gland (50) (50) (49) (50)
Ultimobranchial Cyst 3 (6%)
C-Cell, Hyperplasia 9 (18%) 12 (24%) 5 (10%) 4 (8%)
Follicle, Cyst 4 (8%) 6 (12%) 1 (2%) 2 (4%)
Follicular Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 10 MG/KG 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Edema 1 (2%)
Inflammation, Chronic 1 (2%)
Preputial Gland (50) (48) (50) (50)
Ectasia 4 (8%) 1 (2%) 1 (2%)
Foreign Body 1 (2%) 1 (2%)
Inflammation, Chronic 28 (56%) 23 (48%) 29 (58%) 15 (30%)
Inflammation, Suppurative 11 (22%) 7 (15%) 7 (14%) 3 (6%)
Prostate (50) (50) (50) (50)
Cyst 2 (4%) 1 (2%)
Edema 1 (2%)
Fibrosis 2 (4%) 1 (2%)
Inflammation, Chronic 7 (14%) 2 (4%) 5 (10%) 4 (8%)
Inflammation, Suppurative 25 (50%) 26 (52%) 20 (40%) 15 (30%)
Seminal Vesicle (50) (50) (49) (50)
Edema 1 (2%)
Inflammation, Suppurative 1 (2%)
Testes (50) (50) (50) (50)
Mineralization 26 (52%) 21 (42%) 29 (58%) 14 (28%)
Interstitial Cell, Hyperplasia 2 (4%) 2 (4%) 2 (4%) 2 (4%)
Seminiferous Tubule, Atrophy 5 (10%) 4 (8%) 7 (14%) 5 (10%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Angiectasis 1 (2%)
Hypercellularity 2 (4%) 3 (6%) 6 (12%)
Hyperplasia, Reticulum Cell 1 (2%) 1 (2%)
Hypocellularity 1 (2%) 1 (2%) 2 (4%)
Myelofibrosis 2 (4%)
Lymph Node (50) (50) (50) (50)
Inguinal, Hyperplasia, Lymphoid 1 (2%)
Inguinal, Hyperplasia, Plasma Cell 1 (2%) 1 (2%)
Inguinal, Lymphatic, Dilatation 1 (2%)
Mediastinal, Congestion 1 (2%)
Mediastinal, Hemorrhage 8 (16%) 6 (12%) 10 (20%) 1 (2%)
Mediastinal, Hyperplasia, Lymphoid 1 (2%)
Mediastinal, Hyperplasia, Plasma Cell 5 (10%) 1 (2%) 1 (2%)
Mediastinal, Pigmentation 4 (8%) 8 (16%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 10 MG/KG 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Pancreatic, Hemorrhage 1 (2%)
Pancreatic, Hyperplasia, Lymphoid 2 (4%)
Renal, Hyperplasia, Lymphoid 1 (2%)
Renal, Lymphatic, Dilatation 1 (2%)
Lymph Node, Mandibular (50) (49) (49) (49)
Congestion 1 (2%) 2 (4%) 5 (10%)
Hemorrhage 2 (4%) 1 (2%)
Hyperplasia, Lymphoid 2 (4%) 4 (8%) 2 (4%) 3 (6%)
Hyperplasia, Plasma Cell 19 (38%) 18 (37%) 17 (35%) 5 (10%)
Hyperplasia, Reticulum Cell 1 (2%)
Infiltration Cellular, Polymorphonuclear 1 (2%)
Lymphatic, Dilatation 2 (4%) 6 (12%) 10 (20%) 2 (4%)
Lymph Node, Mesenteric (50) (50) (49) (48)
Congestion 1 (2%)
Erythrophagocytosis 1 (2%) 2 (4%)
Hemorrhage 1 (2%) 1 (2%) 6 (12%) 2 (4%)
Hyperplasia, Lymphoid 1 (2%)
Hyperplasia, Reticulum Cell 1 (2%)
Necrosis 1 (2%) 2 (4%)
Pigmentation 1 (2%)
Lymphatic, Dilatation 1 (2%) 1 (2%)
Spleen (50) (49) (50) (50)
Congestion 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Degeneration, Fatty 1 (2%)
Developmental Malformation 1 (2%)
Fibrosis 2 (4%) 3 (6%) 1 (2%)
Hematopoietic Cell Proliferation 9 (18%) 6 (12%) 7 (14%) 2 (4%)
Hemorrhage 1 (2%)
Hyperplasia, Mononuclear Cell 1 (2%)
Hyperplasia, Re Cell 2 (4%) 2 (4%)
Necrosis 1 (2%) 1 (2%) 3 (6%) 1 (2%)
Pigmentation, Hemosiderin 5 (10%) 7 (14%) 8 (16%)
Lymphoid Follicle, Atrophy 1 (2%)
Red Pulp, Hyperplasia 1 (2%)
Thymus (46) (47) (47) (47)
Congestion 1 (2%) 5 (11%) 13 (28%)
Cyst 3 (7%) 4 (9%) 1 (2%) 1 (2%)
Ectopic Parathyroid Gland 1 (2%)
Hemorrhage 5 (11%) 21 (45%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (48) (49) (50) (47)
Hyperplasia, Cystic 17 (35%) 13 (27%) 11 (22%) 4 (9%)
Hyperplasia, Lobular 2 (4%) 2 (4%)
Skin (50) (49) (50) (50)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 10 MG/KG 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - CONT
Acanthosis 2 (4%) 1 (2%) 1 (2%)
Angiectasis 1 (2%)
Cyst Epithelial Inclusion 1 (2%) 1 (2%) 2 (4%) 1 (2%)
Exudate 1 (2%) 1 (2%)
Fibrosis 1 (2%)
Foreign Body 1 (2%)
Hyperkeratosis 1 (2%) 1 (2%)
Hyperplasia, Basal Cell 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%)
Inflammation, Granulomatous 1 (2%)
Ulcer 1 (2%)
Lip, Hemorrhage 1 (2%)
Scrotum, Congestion 1 (2%) 13 (26%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Femur, Osteopetrosis 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Compression 6 (12%) 4 (8%) 3 (6%) 2 (4%)
Congestion 1 (2%) 4 (8%) 21 (42%)
Degeneration, Focal 1 (2%)
Hemorrhage 1 (2%) 2 (4%) 4 (8%)
Hydrocephalus 1 (2%) 4 (8%) 1 (2%)
Mineralization 1 (2%) 1 (2%)
Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Atelectasis 1 (2%)
Congestion 2 (4%) 3 (6%) 6 (12%) 30 (60%)
Edema 3 (6%) 2 (4%) 1 (2%) 5 (10%)
Foreign Body 3 (6%) 2 (4%)
Hemorrhage 1 (2%) 3 (6%) 2 (4%) 2 (4%)
Infiltration Cellular, Histiocyte 33 (66%) 30 (60%) 28 (56%) 23 (46%)
Inflammation, Chronic 7 (14%) 14 (28%) 10 (20%) 6 (12%)
Inflammation, Subacute 1 (2%)
Inflammation, Suppurative 1 (2%) 2 (4%) 1 (2%)
Leukocytosis 4 (8%)
Metaplasia, Osseous 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 14
NTP Experiment-Test: 05037-03 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC PENTACHLOROANISOLE Date: 06/23/97
Route: GAVAGE Time: 11:29:25
____________________________________________________________________________________________________________________________________
FISCHER 344 RATS MALE VEHICLE 10 MG/KG 20 MG/KG 40 MG/KG
CONTROL
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Alveolar Epithelium, Hyperplasia 6 (12%) 3 (6%) 1 (2%)
Mediastinum, Inflammation, Granulomatous 1 (2%)
Nose (50) (50) (50) (50)
Congestion 3 (6%)
Exudate 17 (34%) 17 (34%) 12 (24%) 9 (18%)
Foreign Body 8 (16%) 6 (12%) 5 (10%) 2 (4%)
Fungus 14 (28%) 15 (30%) 11 (22%) 6 (12%)
Inflammation, Chronic 2 (4%) 7 (14%) 11 (22%) 5 (10%)
Pigmentation 1 (2%)
Mucosa, Erosion 1 (2%)
Mucosa, Hyperplasia 8 (16%) 7 (14%) 7 (14%) 3 (6%)
Mucosa, Metaplasia, Squamous 5 (10%) 8 (16%) 9 (18%) 5 (10%)
Nerve, Hypertrophy 1 (2%) 1 (2%)
Olfactory Epithelium, Pigmentation 29 (58%) 40 (80%) 25 (50%)
Trachea (50) (49) (50) (50)
Exudate 1 (2%)
Mucosa, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (2) (7) (2) (2)
Cataract 1 (50%) 6 (86%) 1 (50%) 1 (50%)
Phthisis Bulbi 1 (50%)
Cornea, Hyperplasia 1 (14%)
Retina, Atrophy 2 (100%) 6 (86%) 1 (50%) 1 (50%)
Sclera, Mineralization 1 (50%) 4 (57%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Congestion 1 (2%)
Cyst 2 (4%) 1 (2%) 3 (6%) 1 (2%)
Hydronephrosis 1 (2%)
Infarct 1 (2%) 1 (2%)
Inflammation, Chronic 38 (76%) 35 (70%) 30 (60%) 20 (40%)
Inflammation, Suppurative 10 (20%) 15 (30%) 20 (40%) 14 (28%)
Mineralization 20 (40%) 13 (26%) 15 (30%) 8 (16%)
Nephropathy 49 (98%) 49 (98%) 46 (92%) 27 (54%)
Artery, Hypertrophy 1 (2%)
Renal Tubule, Pigmentation 1 (2%) 23 (46%) 22 (44%) 16 (32%)
Transitional Epithelium, Hyperplasia 2 (4%) 2 (4%) 1 (2%)
Urethra (2)
Bulbourethral Gland, Ectasia 1 (50%)
Urinary Bladder (50) (50) (50) (50)
Edema 1 (2%) 1 (2%)
Mucosa, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 16
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------